San­thera rene­go­ti­ates mile­stone pay­ment, in­creas­es liq­uid­i­ty run­way in­to 2023 pend­ing NDA fil­ing

Last year, Swiss biotech San­thera Phar­ma­ceu­ti­cals claimed a Phase IIb win for va­morolone for Duchenne — just a few months af­ter ax­ing its pre­vi­ous Duchenne can­di­date af­ter a Phase III fail and trim­ming staff.

Now, with the biotech hop­ing for FDA ap­proval some­time next year, San­thera turned its at­ten­tion to its fi­nances — and some rene­go­ti­at­ing lat­er, it’s opened up some liq­uid­i­ty to hope­ful­ly last the com­pa­ny un­til next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER